Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA1A | P0DMV8 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473253 | 0.77 | HSPA1A (0.40) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL832933 | 0.77 | PTPN7 (0.54) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL6245088 | 0.73 | HSPA1A (0.49) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL1877920 | 0.73 | PTPN7 (0.49) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL10924726 | 0.73 | PTPN7 (0.52) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL1879259 | 0.70 | MAPT (0.47) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL7892118 | 0.68 | PTPN7 (0.53) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL10877400 | 0.67 | HSPA1A (0.49) | HSPA1APTPN7TDP1MAPTMEN1 | |
| SCHEMBL6683356 | 0.65 | ALDH1A1 (0.35) | GAAMAPK1ALDH1A1HPGD | |
| SCHEMBL12203527 | 0.64 | KMT2A (0.61) | HSPA1APTPN7TDP1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | HTR1F, HTR1A, HTR3B | HSPA1A 2862/4885PTPN7 3543/4885TDP1 2974/4885 |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | HTR1F, HTR1A, HTR3B | HSPA1A 2862/4885PTPN7 3543/4885TDP1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.